Enterprise ▸ Industries ▸ Pharmaceuticals ▸Pilots ▸
Pharmaceuticals Pilot #1: Batch & QA
Executive Summary
SagaPharma™ Pilot 1 GMP Batch Release and Quality Assurance
The Breakthrough
Pilot 1 delivers a breakthrough solution for one of the pharmaceutical industry’s most critical and costly pain points: safe, compliant, and rapid batch release under Good Manufacturing Practice (GMP) rules, integrated into a transparent, blockchain-powered global ecosystem on SagaChain™.
The Problem Today
Batch release today often takes days or weeks, requiring manual review of paper or siloed electronic records, multiple signatures, deviation investigations, and fragmented audit trails.
Quality deviations, CAPA workflows, and regulatory audits generate massive administrative overhead and delay market supply.
Counterfeit risks, supply chain diversions, and recall inefficiencies cost the industry billions annually while putting patient safety at risk.
Manufacturers bear high compliance costs, while regulators and payers struggle with delayed or incomplete visibility into quality proofs.
What Pilot 1 Achieves
Pilot 1 delivers a breakthrough solution for one of the pharmaceutical industry’s most critical and costly pain points: safe, compliant, and rapid batch release under Good Manufacturing Practice (GMP) rules, integrated into a transparent, blockchain-powered global ecosystem on SagaChain™.
Real-World Benefits
For Manufacturers & Quality Teams
Cut batch release time and administrative cost by 70–90% from days/weeks to hours or minutes, with audit-ready records available instantly.
Reduce deviation and CAPA overhead through standardized, immutable workflows.
Accelerate market supply and lower inventory carrying costs with faster, safer releases.
For Patients & Healthcare Providers
Greater confidence in medicine quality and authenticity thanks to traceable, tamper-proof batch records.
Faster response to potential safety issues through real-time visibility into release status and deviation history.
For Regulators & Payers
Dramatic reduction in audit and inspection effort continuous, on-chain proofs replace periodic paper submissions.
Industry-wide potential savings in compliance and recall costs estimated in the billions.
Stronger safeguards against counterfeit and diverted products via end-to-end serialization linkage.
Projected total ecosystem value creation: $15–25 billion by 2035 at 50% adoption across major markets.
Available now (on public development testnet) for review and testing
Pilots starts in ~90 days
Low-risk, high-impact, and ready for real batch data and multi-party workflows. We invite pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), quality assurance leaders, regulators (FDA, EMA, WHO observers), standards bodies (GS1, ISO, ICH), and investors to:
- Test the pilot with your own batch and quality data.
- Verify and refine the GMP class extensions and governance rules.
- Co-develop additional regulatory subtrees (e.g., full CAPA workflows, stability studies, Part 11 signatures).
- Join shared custodianship to prepare for global production launch.
More than a technical pilot…
The foundation for a safer, faster, and dramatically more efficient pharmaceutical quality ecosystem.
The pharmaceutical community and investors have a unique opportunity to take custodianship of this transformative GMP framework.
By verifying the architecture, completing regulatory mappings (e.g., full 21 CFR 210/211, EU Annex 11), and collaborating on refinements, you’ll accelerate a global launch that delivers massive operational efficiencies (70–90% faster batch release, real-time audits) and financial gains (billions in savings, reduced recall exposure, enhanced trust).
This open framework empowers manufacturers with streamlined compliance, regulators with continuous oversight, and patients with safer medicines.